About rBIO
Building the future of scalable peptide manufacturing.
rBIO is a biotech manufacturing platform company developing a proprietary process to improve the production economics of essential peptide drugs.
Our story
Founded to address a critical challenge in medicine.
Essential drugs remain too expensive, supply-constrained, and difficult to scale because manufacturing is complex and concentrated.
The company began with insulin, one of the world’s most widely used peptide drugs.
Today, under the leadership of Dr. Deen Bakthavatsalam, CEO and co-founder, rBIO is advancing its proprietary manufacturing process toward commercial-scale readiness and licensing.
Cameron Owen, co-founder, established rBIO’s original business plan and early development path.
Our mission
Improve the economics of essential peptide drug manufacturing.
Through a scalable, proprietary process that can be licensed to qualified partners worldwide.
Our approach
rBIO combines process innovation, manufacturing know-how, and a licensing-first business model to support more efficient production of peptide drugs.
Our first objective is to complete process scale-up and prepare the platform for licensing and partner-enabled commercialization.
Near-term focus
A clear path to process-ready licensing.
Complete scale-up
Advance the insulin process through the next major manufacturing milestone.
Prepare for licensing
Complete the process-development work needed for qualified partners.
Build partnerships
Engage strategic and regional organizations and expand over time.
Leadership
Experience across science, finance and commercialization.
Read biography for Dr. Deen Bakthavatsalam
CEO & Co-Founder
Dr. Deen Bakthavatsalam
Founder and CEO with more than two decades of experience commercializing biotechnology innovations across product development, biomanufacturing, partnerships and company growth. He focuses on turning breakthrough science into scalable businesses that broaden access to affordable peptide therapeutics.
Read biography for Shawn Swaney
CFO
Shawn Swaney
Financial leader supporting high-growth startups through strategy, fundraising, investor relations and disciplined capital planning. His work helps rBIO resource key milestones while maintaining financial strength.
Read biography for Cameron Owen
Co-Founder
Cameron Owen
Founder combining entrepreneurial vision with business development and deal-making. He builds strategic partnerships and translates commercial opportunities into executable growth paths.
Board of directors
Read biography for Stuart Douglass
Executive Chair
Stuart Douglass
Seasoned life-sciences investor and company builder with multiple successful exits. He contributes governance, strategic guidance and a long-term approach to creating shareholder value.
Read biography for Dr. Judith Shizuru
Director
Dr. Judith Shizuru
Stanford physician, Jasper Therapeutics founder, biotech entrepreneur and investor. Her experience in company building, fundraising and investor engagement supports rBIO as it prepares for future financing.
Director
Diane Owen
LinkedIn profile not provided for Diane Owen
Read biography for Diane Owen
Director
Diane Owen
Director of rBIO. A detailed biography is not included in the company’s current published investor materials.
Read biography for Scott Douglass
Director
Scott Douglass
Director of rBIO. A detailed biography is not included in the company’s current published investor materials.
Read biography for Dr. Deen Bakthavatsalam
Director
Dr. Deen Bakthavatsalam
Founder and CEO with more than two decades of experience commercializing biotechnology innovations across product development, biomanufacturing, partnerships and company growth. He focuses on turning breakthrough science into scalable businesses that broaden access to affordable peptide therapeutics.